The<unk>  trials which have led to the acceptance of CRT as a non-pharmacological treatment approach for heart failure enrolled a select group of patients including those with normal sinus rhythm and a QRS duration greater than or equal to 0.15 seconds. A QRS duration greater than or equal to 0.12 seconds has been used as a marker of risk for dyssynchrony and a criterion for selection of patients for CRT.  These<unk>  trials have shown a reduction in mortality of 24% to 36%, a 30% decrease in hospitalization, improved 6 minute walk test, improved NYHA class, and an increase in peak oxygen consumption.
Cardiac resynchronization therapy landmark trials
Antihypertensive and lipid-lowering treatment to prevent heart attack trial
Atrial fibrillation cost-effectiveness of therapy
Chronic stable angina percutaneous coronary intervention versus medical therapy
Pulmonary embolism landmark trials
Chronic stable angina coronary artery bypass grafting versus medical therapy
Chronic stable angina medical therapy
Appropriate use criteria for revascularization